Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

Better Breathing Through Bureaucracy: The FDA’s Half-Century Phenylephrine Saga

by November 8, 2024
November 8, 2024
Better Breathing Through Bureaucracy: The FDA’s Half-Century Phenylephrine Saga

Jeffrey A. Singer

In September 2023, a Food and Drug Administration (FDA) advisory panel informed the agency that, 50 years after the FDA certified phenylephrine hydrochloride as a safe and effective oral decongestant, the evidence suggests it works no better than a placebo. The advisory report came several years after a couple of academic pharmacists had reviewed the research behind the 1970s FDA claims and determined the evidence of efficacy sorely lacking. As I wrote in a blog post that month and a month later in a USA Today column, stomach and intestinal juices break down ingested phenylephrine, rendering it inactive. I hypothesized that, despite the pharmacists’ warnings, the FDA dragged its feet reviewing phenylephrine’s efficacy because it didn’t want to undermine another federal agency’s efforts to wage war on methamphetamines.

When the Combat Methamphetamine Epidemic Act went into effect in 2006, the Drug Enforcement Administration (DEA) ordered all oral decongestants containing pseudoephedrine removed from pharmacy shelves and placed behind the pharmacist’s counter. The DEA also required pharmacists to register customers who bought pseudoephedrine so that law enforcement could monitor their purchases. Furthermore, the DEA put strict limits on the amount of pseudoephedrine a customer could purchase during a 30-day period. This was because many meth dealers at the time were converting pseudoephedrine products they legally purchased into methamphetamine in clandestine labs.

The DEA moves chilled customers who ordinarily purchase products containing pseudoephedrine, which remains an effective decongestant when taken orally. Drugmakers began offering consumers oral decongestants that substituted phenylephrine for pseudoephedrine to help them avoid the queues, surveillance, and stigma of buying pseudoephedrine at the pharmacy counter. More than half of American households trusted and used oral phenylephrine, accounting for an estimated $1.76 billion in sales in 2022.

Of course, we all know what happened next: Mexican drug cartels got into the meth-making business and found more cost-effective ingredients, such as phenyl-2-propanone or P2P, and meth-related deaths soared a whopping 1,400 percent from 2006 to 2020, proving once again that prosecuting the war on drugs is like playing a game of whack-a-mole.

The FDA remained silent when the advisory panel announced its findings 14 months ago. Today, it finally responded. It announced a proposal to order phenylephrine removed from the market as an active ingredient in oral decongestants once it concludes a request for comment period. That period runs from November 8, 2024, until May 7, 2025.

The private sector has been much more agile, as usual. Within a month of the advisory panel’s report, the CVS pharmacy chain announced it was taking oral phenylephrine decongestants off its shelves and would no longer sell them.

CVS, a private company, didn’t want to risk its reputation by keeping customers in the dark about the money they were wasting on oral phenylephrine products. In contrast, the FDA remains in no hurry to inform the public.

0
FacebookTwitterGoogle +Pinterest
previous post
Trump ally floated as possible AG has harsh warning for Letitia James: ‘We will put your fat a– in prison’
next post
Navigating the Intersection of Cybersecurity and Community: An Exclusive Q&A with Matthew Brodacki

You may also like

The Brazilian Judiciary’s Continued Censorship and the Brussels-Brasilia...

August 19, 2024

Trump’s Toast, Folks

August 15, 2023

Friday Feature: Colossal Academy

July 28, 2023

The Cult of the Presidency: 2024 Edition

September 16, 2024

Biden’s Corporate Welfare Bonanza

March 27, 2024

Ten Spending Cuts for President Trump

November 8, 2024

Trump’s Tariff Plan Will Raise Prices for Consumers,...

July 15, 2024

Seven Charts Showing How Canada/Mexico Tariffs Would Harm...

January 29, 2025

The Economist Gets It Wrong on Dollarization in...

September 25, 2023

The War on Prices Continues: Biden’s Misguided Rent...

April 1, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • No, Tariffs Are Not Similar to Consumption Taxes Like a VAT

      August 1, 2025
    • Trump repositions 2 nuclear submarines after ‘highly provocative’ Russian comments

      August 1, 2025
    • Trump endorses ‘MAGA warrior’ for RNC chairman after Whatley launches Senate campaign

      August 1, 2025
    • Friday Feature: Thales Academy

      August 1, 2025
    • Trump ends de minimis tariff exemption, hitting UK exporters and global e-commerce

      August 1, 2025
    • Aston Martin sells F1 team stake for $146m amid financial struggles

      August 1, 2025

    Categories

    • Business (8,651)
    • Investing (2,168)
    • Politics (16,277)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved